119 related articles for article (PubMed ID: 32342528)
1. Release rate determination from in situ gel forming PLGA implant: a novel 'shape-controlled basket in tube' method.
Zhang Q; Fassihi R
J Pharm Pharmacol; 2020 Aug; 72(8):1038-1048. PubMed ID: 32342528
[TBL] [Abstract][Full Text] [Related]
2. Effect of implant formation on drug release kinetics of in situ forming implants.
Suh MS; Kastellorizios M; Tipnis N; Zou Y; Wang Y; Choi S; Burgess DJ
Int J Pharm; 2021 Jan; 592():120105. PubMed ID: 33232755
[TBL] [Abstract][Full Text] [Related]
3. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
[TBL] [Abstract][Full Text] [Related]
4. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
Sheshala R; Hong GC; Yee WP; Meka VS; Thakur RRS
Drug Deliv Transl Res; 2019 Apr; 9(2):534-542. PubMed ID: 29484530
[TBL] [Abstract][Full Text] [Related]
5. Silica particles incorporated into PLGA-based in situ-forming implants exploit the dual advantage of sustained release and particulate delivery.
Thalhauser S; Peterhoff D; Wagner R; Breunig M
Eur J Pharm Biopharm; 2020 Nov; 156():1-10. PubMed ID: 32860903
[TBL] [Abstract][Full Text] [Related]
6. Novel adapter method for in vitro release testing of in situ forming implants.
Wang X; Bao Q; Suh MS; Kastellorizios M; Wang R; Burgess DJ
Int J Pharm; 2022 Jun; 621():121777. PubMed ID: 35489601
[TBL] [Abstract][Full Text] [Related]
7. Polymer degradation induced drug precipitation in PLGA implants - Why less is sometimes more.
Zlomke C; Barth M; Mäder K
Eur J Pharm Biopharm; 2019 Jun; 139():142-152. PubMed ID: 30902733
[TBL] [Abstract][Full Text] [Related]
8. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
9. Long lasting in-situ forming implant loaded with raloxifene HCl: An injectable delivery system for treatment of bone injuries.
Elkasabgy NA; Abdel-Salam FS; Mahmoud AA; Basalious EB; Amer MS; Mostafa AA; Elkheshen SA
Int J Pharm; 2019 Nov; 571():118703. PubMed ID: 31536761
[TBL] [Abstract][Full Text] [Related]
10. Preparation, Optimization and Physicochemical Characterization of Aripiprazole Loaded Nano-porous in situ Forming Implant.
Hedayati A; Yazdi SG; Dehghankelishadi P; Javan NB; Akbari H; Dorkoosh FA
Pharm Nanotechnol; 2017; 5(2):138-147. PubMed ID: 28530539
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive characterization of in situ forming implant diffusivity using diffusion-weighted MRI.
Hopkins KA; Vike N; Li X; Kennedy J; Simmons E; Rispoli J; Solorio L
J Control Release; 2019 Sep; 309():289-301. PubMed ID: 31323243
[TBL] [Abstract][Full Text] [Related]
12. PLGA nanoparticles embedding molybdenum cluster salts: Influence of chemical composition on physico-chemical properties, encapsulation efficiencies, colloidal stabilities and in vitro release.
Dollo G; Boucaud Y; Amela-Cortes M; Molard Y; Cordier S; Brandhonneur N
Int J Pharm; 2020 Feb; 576():119025. PubMed ID: 31926277
[TBL] [Abstract][Full Text] [Related]
13. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
14. Goserelin Acetate Loaded Poloxamer Hydrogel in PLGA Microspheres: Core-Shell Di-Depot Intramuscular Sustained Release Delivery System.
Qi P; Bu R; Zhang H; Yin J; Chen J; Zhang A; Gou J; Yin T; Zhang Y; He H; Wang P; Tang X; Wang Y
Mol Pharm; 2019 Aug; 16(8):3502-3513. PubMed ID: 31251642
[TBL] [Abstract][Full Text] [Related]
15. Double-Controlled Release of Poorly Water-Soluble Paliperidone Palmitate from Self-Assembled Albumin-Oleic Acid Nanoparticles in PLGA in situ Forming Implant.
Yu Y; Ngo HV; Jin G; Tran PHL; Tran TTD; Nguyen VH; Park C; Lee BJ
Int J Nanomedicine; 2021; 16():2819-2831. PubMed ID: 33888982
[TBL] [Abstract][Full Text] [Related]
16. The effect of PLGA molecular weight differences on risperidone release from microspheres.
Kohno M; Andhariya JV; Wan B; Bao Q; Rothstein S; Hezel M; Wang Y; Burgess DJ
Int J Pharm; 2020 May; 582():119339. PubMed ID: 32305366
[TBL] [Abstract][Full Text] [Related]
17. Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug.
Zhang G; Hu J; Meng Q; Wang T; Yang X; Gao L; Quan D
Curr Drug Deliv; 2017; 14(1):47-53. PubMed ID: 27440072
[TBL] [Abstract][Full Text] [Related]
18. In-situ forming implants for the treatment of periodontal diseases: Simultaneous controlled release of an antiseptic and an anti-inflammatory drug.
Lizambard M; Menu T; Fossart M; Bassand C; Agossa K; Huck O; Neut C; Siepmann F
Int J Pharm; 2019 Dec; 572():118833. PubMed ID: 31715363
[TBL] [Abstract][Full Text] [Related]
19. Coloring of PLGA implants to better understand the underlying drug release mechanisms.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2019 Oct; 569():118563. PubMed ID: 31351179
[TBL] [Abstract][Full Text] [Related]
20. In-vitro, ex-vivo, and in-vivo evaluation of buprenorphine HCl release from an in situ forming gel of PLGA-PEG-PLGA using N‑methyl‑2‑pyrrolidone as solvent.
Kamali H; Khodaverdi E; Hadizadeh F; Mohajeri SA
Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():561-575. PubMed ID: 30606566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
